CTOs on the Move


 
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.
  • Number of Employees: 25-100
  • Annual Revenue: $250-500 Million
  • www.olema.com
  • 665 3rd Street Suite 250
    San Francisco, CA USA 94107
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Revive Therapeutics

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.

HospiScript Services

HospiScript Services, LLC is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.

MCR American Pharmaceuticals

MCR American Pharmaceuticals, Inc. was established in 1991. Our product line consists of Allfen, Ambifed, Ambi, Maxifed, Maxinate, Maxiphen, Promacet and Time-Hist QD. Our sales representatives are located throughout the United States. We will continue

KCR

KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.